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1. Introduction 
In 1853, a surgeon at the London Hospital, Adams J, discovered the first case of prostate 
cancer by histological examination [1]. In the report, he noted that the condition was “a very 
rare disease”. Remarkably, 150 years later, prostate cancer has become a significant health 
problem and disease. Prostate cancer continues to have the highest incidence rate of any 
other type of cancer in male, and it is the second leading cause of cancer deaths in male (in 
the United States), with about 220k new cases diagnosed each year only in US [2-4]. 
Detection rates of prostate cancers vary widely across through the world, with less 
frequently detecting in East and South Asia than in Europe, and especially in the United 
States. Prostate cancer tends to develop in men over the age of fifty, and although it is one of 
the most prevalent types of cancer in men. However, many of those patients never have 
symptoms, while undergo no therapy, and eventually die of other causes. The increased 
incidence of prostate cancer patients has led to remarkable changes in diagnosis and 
treatment over the past decades. Fifty years ago the typical patient was a man in his early 
seventies who was diagnosed with metastases to the bone and/or soft tissues [5]. 
Characteristically, these lesions were bulky and histologically poorly differentiated. 
Diagnosis at such an advanced disease status was a death sentence, with patients dying 
within less than two years. Prostate cancer is currently diagnosed by sector biopsy in men 
presenting with an elevated serum prostate-specific antigen level. As for all biopsies, sector 
biopsy for prostate cancer is invasive and limited by sampling error [6]. Now there is a 
genetic and biochemical framework for understanding the process of both sporadic and 
inherited forms of prostate cancer, especially with the development of the new discipline, 
molecular imaging, a valuable tool for the diagnosis for prostate cancer [7]. At present, 
owing to the use of molecular imaging modality, together with the traditional serum PSA 
screening and improved biopsy techniques, most patients could be diagnosed with prostate 
cancer at a stage when it is potentially curable by surgical and/or radiological approaches . 
As a result, the good news is that the diagnosis of prostate cancer is no longer automatically 
a death sentence [8]. 
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Molecular imaging is a newly emerging field, but has became an indispensable tool in 
cancer research, medical practice and clinical trials, with aims at noninvasive, real-time, 
quantitative visualization of in vivo molecular processes occurring at cellular and 
subcellular levels. Molecular imaging allows physicians and clinicians not only to see where 
a tumor is located in the body, but also to visualize the expression and activity of specific 
molecules (small molecular, or large molecular such as protein, antibody, and etc) and 
biological processes (e.g., apoptosis, metastasis, and angiogenesis) which influence tumor 
behavior and/or its response to therapy. At present, advancement in the molecular imaging 
field is promoted by the development of improved imaging hardware for use in preclinical 
and clinical settings, the identification and validation of new, biologically relevant imaging 
targets, and the development of improved imaging probes derived from novel chemicals. Of 
these three essential factors, which comprise the majority of current molecular imaging 
research, hardware developments and novel target discoveries significantly outpace the 
development and clinical advancement of new molecular imaging probes, particularly with 
respect to cancer imaging [9-12]. Hence, molecular imaging, or diagnostic imaging, could 
provide a full prospect of prostate tumor burden by uncovering recurrent and metastatic 
lesions. 
Hererin, we will focus on the discovery of molecular imaging probes that exist for the use of 
molecular imaging as a platform for prostate cancer, rather than specific details of hardware 
and instrumentation. Since molecular imaging probes may also help to guide oncologists, 
physicians and clinicians to identify those patients that could best benefit from a given 
therapeutic regimen, dose, or duration of drug, we will also outline the existing molecular 
imaging probes and modalities that are currently undergoing preclinical and clinical tests 
and those, which have been described based on the different receiptor of prostate cancer, 
that could be rapidly translated into humans. Meanwhile, we will also discuss possible 
future directions and specific application of these and other potential new imaging 
strategies designed to both diagnosis and treatment for prostate cancer. 
2. Imaging probes for prostate cancer based on androgen receptor (AR) 
Androgens are fundamental for the growth, development and maintenance of the prostate. 
Its effects are exerted via the nuclear androgen receptor (AR) which is a ligand-dependent 
transcription activator involved in cellular proliferation and differentiation and is founded 
in all histologic types of prostate tumors. Pathologic and molecular analyses of AR would 
afford the evidence of the gene expression and increased protein mutation, which 
contributes to a change of function, and ligand-independent activation [13, 14]. Since it is 
particularly imperative to find approaches for assessing prostate cancer comprehensively, 
molecular imaging of AR might provide an unprecedented opportunity for deciphering the 
molecular mechanisms involved in the development and natural progression of prostate 
cancer from a localized process to the hormone-refractory metastatic disease. Such 
understanding will be the key for targeted imaging and therapy, as well as for predicting 
and evaluating treatment response and prognosis [15]. An alternative approach to 
radiolabeled antibodies, such as 111In-labeled prostate-specific membrane antigen (PSMA) 
monoclonal antibody (also named as ProstaScint) was reported, with a focus on the 
development of AR radioligands for positron emission tomography (PET), single photon 
emission computerized tomography (SPECT), and magnatic resonance imaging (MRI)-based 
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imaging of the prostate. Generally speaking, AR radiolabeled ligands can be divided into two 
main structural classes, steroidal (such as 18F-FDHT) and nonsteroidal (such as flutamide and 
bicalutamide), or into two different functional classes, androgenic and antiandrogenic [16, 17].  
2.1 Steroidal AR radioligands for imaging prostate cancer 
Zanzonico P and co-workers discovered a steroidal AR radioligand, 18F-FDHT (16ǃ-
[18F]fluoro-5R-dihydrotestosterone), and carried out some basic research to evaluate it [18, 
19]. FDHT is of a structural analog of 5R-di-hydrotestosterone, a principal intraprostatic 
form of androgen. A study of progressive androgen-independent prostate cancer on seven 
patients indicated that 18F-FDHT may be a promising new radiotracer compare with 18F-
FDG. In the relevant study of fluorinated androgen analogs in baboon, performed by Welch 
group, the uptake of FDHT in the prostate was blocked by coadministration of cold 
tesosterone (reduced about 10-fold) [20]. To date, FDHT appears to bind specifically to 
androgen receptors in vivo and to be of the most favorable targeting properties for 
noninvasive imaging among all receptor-binding radiotracers studied before. In other 
researches, 18F-FDHT present some advantages such as fast tumor uptake and prolonged 
retention of radioactivity observed in human studies. However, limitations such as 
metabolic rate of this labeled compound rapid have been observed [21-23]. 
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Scheme 1. The chemical structure of Testosterone and 18F-FDHT. 
2.2 Nonsteroidal AR radioligands for imaging prostate cancer 
Nonsteroidal AR radioligands, (R)-[11C]-dimethylaminehydroxy-flutamide derivatives 
(Scheme 2, probe 2, 3, and 4), were designed, synthesized and radiosynthesised by Jacobson O 
et al in 2006 [24]. The preliminary biological evaluations of three novel nonsteroidal flutamide 
derivative androgen ligands demonstrated some significant benefits compared with the 
currently used commercial drugs. These compounds have higher or similar affinities to the AR 
when compared with 3-bromo-hydroxyflutamide and hydroxyflutamide. However, unlike 
other reported nonsteroidal radiolabeled AR ligands, these compounds have an electron-rich 
group (dimethylamine) located on the methyl moiety, which may confer a better stability to 
the molecule. Additionally, they serve as an anchor for carbon-11 labeling in a more 
straightforward approach than labeling with fluorine-18 or bromine-76. Furthermore, some 
other nonsteroidal agents are being evaluated for prostate cancer imaging, based on 
hydroxyflutamide and bicalutamide pharmacophores, for example, as shown in Scheme 2, (R)-
[18F]-hydroxyflutamide (5), 3-[76Br]-bromo-hydroxyflutamide (6), [18F]- bicalutamide (7), 
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Scheme 2. Chemical structures of some nonsteroidal AR radioligands for imaging prostate 
cancer. 
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[76Br]-bromo-bicalutamide (8), and [76Br]-bromo-thiobicalutamide (9) [25, 26]. Additionally, 
[76Br]-bromo-bicalutamide compound has been found  to have an order of magnitude 
higher affinity for AR than that of bicalutamide (Kd of 0.113 μM for [76Br]-bromobica-
lutamide versus to Kd of 1.276 μM for bicalutamide). Also, a series of novel prospective 
SPECT imaging agents has been reported very recently. These 99mTc-containing flutamide 
derivatives (10, 11) were synthesized, characterized, and evaluated, with a significant 
selective uptake by a prostate [27]. Furthermore, Marom H et al reported a new nonsteroidal 
antiandrogen-lanthanoid metal complexes (12) as a potential MRI contrast agent for prostate 
cancer diagnostics [28]. These interesting results demonstrate that AR provides a more 
sensitive imaging-based biologic target for imaging and early assessment of treatment 
response. 
3. Imaging probes for prostate cancer based on PSMA 
Serum prostate-specific antigen (PSA) has long been used as an organ-specific biomarker 
and is currently the most commonly used one for prostate cancer. PSA is a 33 kDa 
androgen-regulated serine protease produced by the prostate gland. However, PSA and 
other related parameters have limited sensitivity and limited specificity to prostate cancer. 
Therefore, it may be affected by a manner unrelated to the effect of the therapy on tumor, 
and is the cause of the patients' great anxiety or overstated diagnostic expectations [29, 30]. 
The prostate-specific membrane antigen (PSMA) is expressed in both the benign and the 
neoplastic prostatic epithelial cells and in other tissues, such as kidney, liver, and brain [31]. 
It is upregulated in hormone-resistant states and in metastatic disease. It is a 
transmembrane, 750 amino acid, type II glycoprotein primarily expressed in normal human 
prostate epithelium but overexpressed in prostate cancer, including metastatic disease. 
Because PSMA is expressed by virtually all prostate cancers and its expression is further 
increased in poorly differentiated, metastatic and hormone-refractory carcinomas, it is a 
very attractive target for prostate cancer imaging and therapy [32, 33]. Recently, researchers 
from Johns Hopkins University presented the preparation of radiolabeled small-molecule 
ligands for PSMA ([125I]DCIT, [11C]DCMC, [18F]DCFBC], as well as seven technetium 
99m- or rhenium-labeled chelating agents attached to an amino-functionalized PSMA 
inhibitor with or without a variable length linker moiety [34-36]. These probes were based 
on potential capitalization on PSMA as a relevant biologic target for imaging and therapy of 
prostate cancer. Other works indicated that biotinylated anti-PSMA antibody conjugated to 
streptavidin-labeled iron oxide nanoparticles could be used as the MRI probe for detection 
of prostate cancer cells [37]. T1-weighted signal was greater for cells with magnetic 
particles bound to cell surface than for cells that internalized the particles, whereas no 
such effect was noted with T2-weighted images. Besides, a low molecular weight PSMA-
based fluorescent imaging agent have been relatively extensively studied in prostate 
cancer. 2-(3-(5-[7-(5-amino-1-carboxy-pentyl-carbamoyl)-heptanoy-amino]-1-carboxy-
pentyl)-ureido) entanedioic acid was conjugated with a commercially available near-
infrared light-emitting dye (IRDye 800CW) to afford 16 in good yield. It has a PSMA 
inhibitory activity of 0.37 nM, which is capable of generating target-to-nontarget ratios of at 
least 10 fold in PSMA-expressing PC3-PIP vs PSMA-negative PC3-flu tumors in vivo. It is 
useful for the study of PSMA-expressing tissue in preclinical models or for intraoperative 
guidance [38].  
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Scheme 3. Probes for imaging prostate cancer based on PSMA. 
4. Other probes for imaging prostate cancer based on EGF receptor, GRP 
receptor, and integrin αvβ3 
[18F]-fluorodeoxyglucose (FDG) (17) is a well known molecular imaging probe for 
monitoring tissue glucose metabolism in clinical trial [39, 40]. Because of the advantages of 
the known mechanism that most tumors are hypermetabolic with increased glucose 
metabolism (Warburg effect), this probe is more suitable for assessing the glucose 
metabolism for prostate cancer. The upregulation of glucose transporter (GLUT) proteins 
(such as GLUT1 and/or GLUT3) and/or increased enzymatic level of hexokinase (HK) and 
activity (primarily HK-II) have been observed in many cancers. GLUT, which affects the 
rate-limiting step, is very important for glucose metabolism. The whole procedure needs 
energy-independent glucose transport across the cell membrane down the concentration 
gradient. Then, glucose is phosphorylated to glucose-6-phosphate by efficiently using HK-II. 
FDG, with a similar structure to glucose, is phosphorylated to FDG-6-phosphate, but when 
compared with glucose-6-phosphate, it cannot be further metabolized in the glycolytic 
pathway and finally trapped and accumulated in the cell owing to its negative charge [41, 
42]. The GLUT1 mRNA expression was observed by Northern blot analysis in both 
androgen-independent cell lines and the androgen-sensitive prostate cancer cell line [43]. A 
related study from Australia demonstrated that the expression of GLUT12 in human 
prostate cancer cell lines potentially enhanced glucose metabolism in prostate tumor [44]. 
These findings may explain the phenomenon of higher FDG accumulation in prostate 
cancer, especially in malignancy grade. However, there are some limitations: the role of 18F-
FDG PET in prostate cancer is controversial, and the results are heavily influenced by the 
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patient selection; The uptake of 18F-FDG is low in tumour tissue. The 60%–70% sensitivity 
of 18F-FDG PET for prostate cancer is not high enough to justify its routine clinical use for 
staging or restaging of this disease [45]. The poor performance of 18F-FDG PET is likely 
related to the low glucose metabolic rate that results from the relatively slow growth of most 
prostate cancers as well as to other factors.  
Another PET tracers, such as 11C- or 18F-labeled acetate (18, 19) and choline (20, 21), have 
been extensively studied in prostate cancer [46, 47]. However, 11C acetate is primarily 
retained in prostate cancer cell lines, due to incorporation of the radiocarbon into 
phosphatidylcholine and neutral lipids of the cells [48]. Meanwhile, because of the alteration 
in several enzymes involved in the metabolism of fatty acids and enhanced beta-oxidation 
pathway, it has been observed that fatty acid metabolism rather than glycolysis may be 
dominant in prostate cancer [49]. Recent studies also confirmed that the involvement of the 
fatty acid synthesis pathway in 11C acetate uptake in prostate tumors is an imaging marker 
for fatty acid synthesis expression [50]. Previous clinical studies with 11C- labeled acetate 
(11C-ACE) have reported improved sensitivity, up to 100%, for detection of primary tumors 
in patients with untreated prostate cancer [51, 52]. However, the potential for widespread 
use of 11C-ACE is limited by the short radioactive half-life (20.4 min) of 11C. Accordingly, 
there is considerable interest in identifying positron-emitting radiopharmaceuticals labeled 
with isotopes with longer half-lives that are suitable for imaging of prostate cancer. One 
such radiopharmaceutical that has been studied is 18F-fluoroethylcholine, which also 
appears to be a cell membrane precursor compound [53, 54]. Another potential agent is the 
acetate analog 18F-fluoroacetate (18F-FAC). Fatty acid synthesis is an important pathway in 
cancer cell, which requires major enzyme for converting carbohydrates to fatty acids, and 
the upregulation of the relevant enzyme plays a key role in tumorigenesis of the prostate in 
the transgenic adenocarcinoma of mouse prostate (TRAMP) model [55]. Recently, 
[11C]acetoacetate (22) has also been evaluated as a potential PET probe of ketone body use 
by prostate tumors [56]. It was found that PC-3 androgen-independent prostate tumors 
display moderated uptake of [11C] acetoacetate with rapidly decreasing background 
activity. Further research would be needed to determine the exact biologic relevance of 
imaging ketone body use to the natural history of prostate cancer and how it may be useful 
in a specific clinical setting. 
The epidermal growth factor receptor (EGFR) is over-expressed in a variety of human 
cancers, including in hormone-refractory prostate carcinomas, in which the EGFR has been 
associated with advanced disease stage, resistance to standard treatment and poor 
prognosis. Therefore, the EGFR is considered to be a promising molecular target for 
molecular imaging and therapy for hormone-refractory prostate cancer. Fozing T reported a 
synthesis an EGF receptor tyrosine kinase (EGFR-TK) inhibitor, 123I-PD153035 (23) as 
potential imaging probes. In vitro studies of 123I-PD153035 was found that it accumulats 
highly in human PC-3 and DU-145 prostate cancer cells cooperating with 123I-mAb425, the 
123I radiolabelled IgG2a antibody [57]. In vivo studies of the human prostate cancer 
xenografts in mouse was accurately visualized after i.v. administration of 123I-PD153035 by 
a gamma camera. These data suggest that 123I-PD153035 are promising candidates as an 
imaging probe for EGFR- positive prostate cancer and warrant further in vivo validations to 
ascertain their potential as imaging agents for clinical used. Another radiolabeled bombesin 
(a target molecular with high affinity for GRP receptors) analogues was synthesized and 
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assessed for SPECT (111In label) and PET (64Cu or 18F label) visualization of prostate cancer 
[58, 59]. However, imaging of the GRP receptor is being under the further investigation to 
determine whether it is useful or not in clinical trial for prostate cancer. 
In relation to tumor angiogenesis, the vascular endothelial growth factor (VEGF) signaling 
pathway and the integrin ǂvǃ3 (a cell adhesion molecule) have been identified to play key 
roles. Molecular imaging of these targets in the tumor vasculature may help tailor targeted 
antiangiogenic therapy [60]. Some of PET probes suitable for integrin receptor imaging have 
been reported, and have shown high specificity in various types of tumors, including 
prostate cancer models [61]. Active research continues in identifying more specific biologic 
markers for interrogating the tumor vessels. These investigations will not only shed more 
light on the biologic basis of the complex signals involved in malignancy-induced 
angiogenesis, but may also help facilitate the design and image-based testing of drugs 
targeted to tumor-specific angiogenesis. 
 
Scheme 4. Other small molecular imaging probes for prostate cancer. 
5. Conclusion  
Molecular imaging probes represent an important, growing class of chemical compounds 
for biology, pharmaceutical sciences, preclinic and clinic studies and further application. In 
conjunction with the imaging modality (such as PET, SPECT, MRI and etc), the 
identification of molecular imaging targets and the development of new labeled molecular 
probes for those targets are crucial for expanding the capability of in vivo molecular 
imaging for biological research, molecular diagnostics and drug discovery. In the post 
genomics era, there is the opportunity to advance probes to the point where they can target 
specific biochemical signatures associated with disease, including prostate cancer. Because 
changes in biochemistry occur before diseases reach an advanced stage, molecular imaging 
probes will foster earlier and more personalized diagnosis of disease. Herein, the abilities of 
various probes to assess different functional and molecular characteristics for prostate 
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cancer are being explored and reviewed. The advantages and limitations of imaging agents 
for prostate cancer were outlined in Table 1.  
Table 1.Advantages and limitations of probes used in clinical and preclinical trials for 
prostate cancer. 
Probes for 
prostate 
cancer 
Advantages Limitations Reference 
1 fast tumor uptake, prolonged 
retention of radioactivity 
rapid metabolic rate, not 
sensitive enough 
21, 22, 23 
2, 3, 4 stablity, easy for 11C label, 
high affinity 
instability of the 11C 
labeled precursor, low 
radiolabeled yield 
24 
13, 14, 15 easy for synthesization, 
specificity, muti-labeled 
methods 
not specific enough (mouse 
kidneys, also express 
PSMA) 
31, 33, 34, 
35, 36, 
17 clinical use, safety not sensitive enough, low 
cellular uptake 
39, 40, 41 
18, 19 clinical use, high uptake short physical half-life of 
positron-emitting 
radionuclide (19) 
51, 52 
20, 21 clinical use, high sensitivity 
and specificity, suitable for 
PET (20) 
short physical half-life of 
positron-emitting 
radionuclide (21) 
53, 54 
6. Perspective  
Currently, imaging probes for prostate cancer are focused on the construction that yield an 
increased selectivity and sensitiveness of measurements per examination, thus higher 
resolution and quantification accuracy is required. Due to the complication of case 
difference and personalized conditions, more accurate and more efficient forward and 
inversion problems for improving the quantification accuracy will be speed up. The design, 
synthesis and application of dual- and multi-modality probe will be a hot research area, 
which may be the next generation of probe. The combination of different fuctional modality 
undoubtly will improve the accuracy of diagnosis and analysis to prostate cancer. On the 
other hand, a targeted gene-therapy approach is also being developed to activate the 
immune system to recognize prostate cancer cells. To discovery probes based on labeled 
gene and related macromelecule and these types of approaches might provide a new 
direction of prostate cancer therapies. We believe that such imaging probes will play a vital 
role in our further understanding of prostate cancer, in early detection and in the design of 
effective treatments. 
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